Sender Company & Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Sender Company & Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,724	Closed	-$210K	–	120
2025 Q4	$210K	Sell	1,724 -3,543	-67%	-$406K	0.1%	90
2025 Q3	$528K	Buy	5,267 +69	+1%	+$6.21K	0.06%	249
2025 Q2	$431K	Buy	+5,198	New	+$415K	0.12%	155
2024 Q2	–	Sell	-18,108	Closed	-$1.72M	–	53
2024 Q1	$1.72M	Buy	+18,108	New	+$1.68M	2.95%	7
2022 Q2	–	Sell	-9,245	Closed	-$831K	–	60
2022 Q1	$831K	Sell	9,245 -72,196	-89%	-$6.67M	0.89%	24
2021 Q4	$9.12M	Buy	+81,441	New	+$9.82M	4.67%	2

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sender Company & Partners's XBI Position: Q1 2026 in Review

Sender Company & Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 1,724 shares — an estimated $210K sold.

Sender Company & Partners first reported a position in XBI in Q4 2021 and held it in 6 quarters. The position peaked at $9.12M in Q4 2021. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Sender Company & Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
Sender Company & Partners sold 1,724 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $210K.
Sender Company & Partners first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and held it in 6 quarters.
Sender Company & Partners's State Street SPDR S&P Biotech ETF position peaked at $9.12M in Q4 2021.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Sender Company & Partners's 13F filing for Q1 2026, filed 15 May 2026.